Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Phase 2

NNC0194-0499, Cagrilintide, SemaglutideEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Sponsor:

Novo Nordisk A/S

Code:

NCT06409130

Conditions

Alcohol-related Liver Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NNC0194-0499

Semaglutide

NNC0194-0499 placebo

Semaglutide placebo (Group A)

Cagrilintide + semaglutide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-30. This information was provided to ClinicalTrials.gov by Novo Nordisk A/S on 2025-05-18.